Literature DB >> 22826139

Analysis of multi-stage treatments for recurrent diseases.

Xuelin Huang1, Jing Ning.   

Abstract

Patients with a non-curable disease such as many types of cancer usually go through the process of initial treatment, a various number of disease recurrences and salvage treatments, and eventually death. The analysis of the effects of initial and salvage treatments on overall survival is not trivial. One may try to use disease recurrences and salvage treatments as time-dependent covariates in a Cox proportional hazards model. However, because disease recurrence is an intermediate outcome between initial treatment and final survival, the interpretation of such an estimation result is awkward. It does not estimate the causal effects of treatments on overall survival. Nevertheless, such causal effect estimates are critical for treatment decision making. Our approach to address this issue is that, at any treatment stage, for each patient, we compute a potential survival time if he or she would receive the optimal subsequent treatments, and use this potential survival time to do comparison between current-stage treatment groups. This potential survival time is assumed to follow an accelerated failure time model at each treatment stage and calculated by backward induction, starting from the last stage of treatment. By doing that, the effects on survival of different treatments at each stage can be consistently estimated and fairly compared. Under suitable conditions, these estimated effects have a causal interpretation. We evaluated the proposed model and estimation method by simulation studies and illustrated using the motivating, real data set that describes initial and salvage treatments for patients with soft tissue sarcoma.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22826139      PMCID: PMC3500149          DOI: 10.1002/sim.5456

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  12 in total

1.  Nonparametric analysis of recurrent events and death.

Authors:  D Ghosh; D Y Lin
Journal:  Biometrics       Date:  2000-06       Impact factor: 2.571

2.  Shared frailty models for recurrent events and a terminal event.

Authors:  Lei Liu; Robert A Wolfe; Xuelin Huang
Journal:  Biometrics       Date:  2004-09       Impact factor: 2.571

3.  Regression modeling of semicompeting risks data.

Authors:  Limin Peng; Jason P Fine
Journal:  Biometrics       Date:  2007-03       Impact factor: 2.571

4.  A joint frailty model for survival and gap times between recurrent events.

Authors:  Xuelin Huang; Lei Liu
Journal:  Biometrics       Date:  2007-06       Impact factor: 2.571

5.  Assessing the sensitivity of regression results to unmeasured confounders in observational studies.

Authors:  D Y Lin; B M Psaty; R A Kronmal
Journal:  Biometrics       Date:  1998-09       Impact factor: 2.571

6.  Marginal analysis of recurrent events and a terminating event.

Authors:  R J Cook; J F Lawless
Journal:  Stat Med       Date:  1997-04-30       Impact factor: 2.373

7.  Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities.

Authors:  P W Pisters; D H Leung; J Woodruff; W Shi; M F Brennan
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

8.  Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group.

Authors:  J M Coindre; P Terrier; N B Bui; F Bonichon; F Collin; V Le Doussal; A M Mandard; M O Vilain; J Jacquemier; H Duplay; X Sastre; C Barlier; M Henry-Amar; J Macé-Lesech; G Contesso
Journal:  J Clin Oncol       Date:  1996-03       Impact factor: 44.544

9.  Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients.

Authors:  Gunar K Zagars; Matthew T Ballo; Peter W T Pisters; Raphael E Pollock; Shreyaskumar R Patel; Robert S Benjamin; Harry L Evans
Journal:  Cancer       Date:  2003-05-15       Impact factor: 6.860

10.  Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes.

Authors:  Janice N Cormier; Xuelin Huang; Yan Xing; Peter F Thall; Xuemei Wang; Robert S Benjamin; Raphael E Pollock; Cristina R Antonescu; Robert G Maki; Murray F Brennan; Peter W T Pisters
Journal:  J Clin Oncol       Date:  2004-11-15       Impact factor: 44.544

View more
  5 in total

1.  Tools for the Precision Medicine Era: How to Develop Highly Personalized Treatment Recommendations From Cohort and Registry Data Using Q-Learning.

Authors:  Elizabeth F Krakow; Michael Hemmer; Tao Wang; Brent Logan; Mukta Arora; Stephen Spellman; Daniel Couriel; Amin Alousi; Joseph Pidala; Michael Last; Silvy Lachance; Erica E M Moodie
Journal:  Am J Epidemiol       Date:  2017-07-15       Impact factor: 4.897

2.  A cure-rate model for Q-learning: Estimating an adaptive immunosuppressant treatment strategy for allogeneic hematopoietic cell transplant patients.

Authors:  Erica E M Moodie; David A Stephens; Shomoita Alam; Mei-Jie Zhang; Brent Logan; Mukta Arora; Stephen Spellman; Elizabeth F Krakow
Journal:  Biom J       Date:  2018-05-16       Impact factor: 2.207

3.  Optimization of individualized dynamic treatment regimes for recurrent diseases.

Authors:  Xuelin Huang; Jing Ning; Abdus S Wahed
Journal:  Stat Med       Date:  2014-02-09       Impact factor: 2.373

4.  Interactive Q-learning for Quantiles.

Authors:  Kristin A Linn; Eric B Laber; Leonard A Stefanski
Journal:  J Am Stat Assoc       Date:  2017-03-31       Impact factor: 5.033

Review 5.  A scoping review of studies using observational data to optimise dynamic treatment regimens.

Authors:  Maarten J IJzerman; Julie A Simpson; Robert K Mahar; Myra B McGuinness; Bibhas Chakraborty; John B Carlin
Journal:  BMC Med Res Methodol       Date:  2021-02-22       Impact factor: 4.615

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.